V
26.95
2.09 (8.41%)
| 前收盘价格 | 24.86 |
| 收盘价格 | 25.30 |
| 成交量 | 4,356,088 |
| 平均成交量 (3个月) | 3,808,385 |
| 市值 | 3,026,754,560 |
| 股市价格/股市净资产 (P/B) | 3.30 |
| 52周波幅 | |
| 利润日期 | 22 Jul 2025 - 28 Jul 2025 |
| 稀释每股收益 (EPS TTM) | -1.16 |
| 总债务/股东权益 (D/E MRQ) | 0.12% |
| 流动比率 (MRQ) | 44.25 |
| 营业现金流 (OCF TTM) | -133.99 M |
| 杠杆自由现金流 (LFCF TTM) | -98.38 M |
| 资产报酬率 (ROA TTM) | -11.74% |
| 股东权益报酬率 (ROE TTM) | -14.40% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Viking Therapeutics, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
3.1
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | 4.5 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 3.13 |
|
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 2.12% |
| 机构持股比例 | 70.04% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 104.00 (Cantor Fitzgerald, 285.90%) | 购买 |
| 中 | 102.00 (278.48%) | |
| 低 | 30.00 (Goldman Sachs, 11.32%) | 保留 |
| 平均值 | 82.60 (206.49%) | |
| 总计 | 4 购买, 1 保留 | |
| 平均价格@调整类型 | 24.89 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 25 Jun 2025 | 102.00 (278.48%) | 购买 | 26.95 |
| 24 Apr 2025 | 102.00 (278.48%) | 购买 | 25.66 | |
| Cantor Fitzgerald | 28 Apr 2025 | 104.00 (285.90%) | 购买 | 25.94 |
| Truist Securities | 28 Apr 2025 | 75.00 (178.29%) | 购买 | 25.94 |
| Morgan Stanley | 24 Apr 2025 | 102.00 (278.48%) | 购买 | 25.66 |
| Goldman Sachs | 08 Apr 2025 | 30.00 (11.32%) | 保留 | 19.98 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合